Stay current on investigational and U.S. Food and Drug Administration-approved immune and molecular-targeted therapies, from common side effects to treatment algorithms. You’ll explore anti-CTLA4 antibodies, anti-PD1 antibodies, and BRAF and MEK inhibitors. Other key topics include CKIT-, NRAS-, and CMET-targeted therapies.
Objectives1. Identify current immune-modulating therapies and immune-related adverse events.
2. Plan treatment algorithms for immune-related adverse events.
3. Evaluate the ability to use molecular-targeted therapies for melanoma treatment based on identified somatic mutations.
ILNAThis session qualifies for the following ONCC Individual Learning Needs Assessment (ILNA) categories.
OCN®: Scientific Basis for Practice, Treatment Modalities
AOCNP®: Diagnosis, Staging, and Treatment Planning, Cancer Treatment
AOCNS®: Diagnosis, Staging, and Treatment Planning, Cancer Treatment